Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints

Egarter, Ch.; Huber, Johannes; Leikermoser, R.; Haidbauer, R.; Pusch, H.; Fischl, Franz; Putz, Marietta

doi:10.1016/0378-5122(95)00953-1

Cited by 81 publications

(43 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, as the findings after 12 months of treatment were generally comparable with those seen earlier, any effect due to this type of analysis appears minimal. Furthermore, the improvement in these assessments confirms previous findings from tibolone studies 21,22,34,35 .…”

Section: Discussionsupporting

confidence: 80%

“…The results of the GCS questionnaire show both agents effectively treat climacteric symptoms, as demonstrated in previous studies 5, 21,22 . There was no difference in total GCS score between the tibolone and CEE -MPA groups; however, there was a small, but significant, improvement in vasomotor subscore in the CEE -MPA group compared with the tibolone group.…”

Section: Discussionsupporting

confidence: 54%

See 1 more Smart Citation

Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women

Huber¹

2002

BJOG: An International Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

Objective To compare the effects of tibolone and conjugated equine oestrogens continuously combined with medroxyprogesterone acetate on bleeding rates, quality of life (QoL) and tolerability. Design A double-blind, randomised comparative trial.Setting Thirty-seven centres in six European countries.Population Five hundred and one postmenopausal women, under 65 years of age with an intact uterus.Interventions For 12 months, women received daily treatment with tibolone 2.5 mg (n ¼ 250), or conjugated equine oestrogens 0.625 mg continuously combined with medroxyprogesterone acetate 5 mg (CEE-MPA, n ¼ 251). Main outcome measures The primary outcome was vaginal bleeding rate during cycles 4 -6. The secondary outcomes were vaginal bleeding rate during cycles 1 -3, 7-9 and 10 -13, cumulative bleeding rate, QoL, wellbeing, climacteric symptoms, urogenital complaints and tolerability. Results Treatment with tibolone led to a significantly lower bleeding rate during cycles 4 -6 compared with CEE -MPA (15.0% vs 26.9%; P ¼ 0.004); there was a similar difference during cycles 1-3. Both treatments improved QoL, wellbeing, climacteric symptoms and urogenital complaints. By intent-to-treat analysis, tibolone significantly improved sexual drive, interest and/or performance, compared with CEE -MPA at 12 months ( P ¼ 0.017). Although both treatments were well tolerated, there was a significantly lower incidence of breast tenderness with tibolone than CEE -MPA (2.4% vs 17.1%; P < 0.001). Conclusion The vaginal bleeding rate during cycles 4-6 was significantly lower in women using tibolone.Both treatments improved QoL, wellbeing, climacteric symptoms and urogenital symptoms. Breast tenderness was significantly less frequent with tibolone.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionsupporting

confidence: 54%

Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women

Huber¹

2002

BJOG: An International Journal of Obstetrics and Gynaecology

View full text Add to dashboard Cite

show abstract

“…The D4-isomer can bind and transactivate the progesterone receptor and the androgen receptor, such that in the endometrium tibolone exerts a predominantly progestogenic effect [88]. Tibolone alleviates postmenopausal vasomotor symptoms [89] without stimulating the endometrium [90]. Hence, a progestogen is not required and cyclical bleeding is not induced.…”

Section: Tibolonementioning

confidence: 99%

Drugs for the treatment of menopausal symptoms

Davis

Jane

2010

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

“…Tibolone normalises the vaginal karyopyknotic and maturation indices and alleviates symptomatic atrophic vaginitis (Botsis et al 1997, Morris et al 1999) and women treated with tibolone report significant reductions in vaginal dryness and dyspareunia, effects which may be secondary to both oestrogenic and androgenic actions. Randomised studies indicate tibolone has positive effects on mood compared with placebo and alleviates several adverse mood parameters to a similar extent as conventional HT (Egarter et al 1996). Tibolone and its 4-isomer transactivate the AR and exert androgenic effects (Moore 2001), which significantly lowers SHBG, further adding to its androgenicity (Doren et al 2001).…”

Section: Tibolone and Tissue Specific Steroid Activationmentioning

confidence: 99%

Postmenopausal hormone therapy: from monkey glands to transdermal patches

Davis

Dinatale²,

Rivera-Woll³

et al. 2005

Journal of Endocrinology

View full text Add to dashboard Cite

The climacteric is not a condition of the modern age, although with increased life expectancy over the centuries, more women will experience this physiological transition. As women are living longer there is a greater expectation that good health will be maintained through to the late decade. Thus the potential long-term adverse health consequences of using hormonal therapies (HTs) to alleviate menopausal symptoms are of considerable concern for women and medical practitioners. This concern is often the basis for a decision whether or not to use HT.We have reviewed the history of knowledge of the menopause and the development of HT for the treatment of climacteric complaints. We have also summarised the current evidence for specific benefits and risks of HT. Data indicate that postmenopausal HT is appropriate for the management of vasomotor symptoms, but that HT should not be prescribed for the prevention of cardiovascular disease or dementia. HT does prevent bone loss and osteoporotic fracture; however, use for this purpose remains controversial. The risk of breast cancer with HT varies according to the preparation used, such that oestrogen without concurrent progestin appears to convey little, or possibly even no significant breast cancer risk. There is insufficient information regarding the long-term use of non-oral HT, low-dose HT or novel compounds such as tibolone or the selective oestrogen receptor modulators with respect to breast cancer and cardiovascular risk for specific recommendations to be made.

show abstract

Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints

Cited by 81 publications

References 12 publications

Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women

Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women

Drugs for the treatment of menopausal symptoms

Postmenopausal hormone therapy: from monkey glands to transdermal patches

Contact Info

Product

Resources

About